Role of Glutamine in Cancer: Therapeutic and Imaging Implications

Kartik N. Rajagopalan and Ralph J. DeBerardinis

Department of Pediatrics and McDermott Center for Human Growth and Development, University of Texas–Southwestern Medical Center, Dallas, Texas

Metabolic imaging has great clinical potential in cancer because perturbations of metabolism are common hallmarks of malignant cellular transformation. Novel imaging strategies focused on glutamine could provide a valuable complement to ^{18}F-FDG PET, because glutamine complements glucose in the metabolic platforms that support tumor growth at the cellular level. Furthermore, recent work has demonstrated that distinct aspects of glutamine metabolism are under the control of oncogenes and tumor suppressors. It is plausible that imaging glutamine metabolism could predict both the presence of specific transforming mutations in the tumor and the sensitivity to therapeutic agents designed to target glutamine use. Here, we review the essential aspects of glutamine metabolism in cancer cells and discuss opportunities for imaging in cancer patients.

Molecular imaging in cancer has the potential to noninvasively illuminate biologic properties of a tumor in order to individualize treatment and improve the accuracy of prognosis counseling. Although conventional anatomic imaging offers crucial information about tumor size and location, it provides little insight into the molecular characteristics of the tumor. Imaging key aspects of tumor metabolism adds an informative dimension to existing modalities because metabolism reports many clinically relevant aspects of tumor biology, including histologic grade, aggressiveness, and effects of the microenvironment. Warburg's seminal work on cancer metabolism in the 1920s, in particular his observation that some tumors have high rates of glucose uptake relative to normal tissue, paved the way for ^{18}F-FDG PET, now the most commonly used form of metabolic imaging. This technique capitalizes on the fact that enhanced glucose uptake is a common effect of many of the mutations that lead to malignant transformation (*1*). It is used in the clinic to pinpoint the location and distribution of tumor tissue, to determine therapeutic response, and to monitor for recurrence.

Despite the success of ^{18}F-FDG PET in clinical oncology, the information it provides about tumor metabolism is actually quite limited. Because PET provides no information about the fate of the tracer after it enters the tumor, the user is unaware of subtleties of intracellular tumor glucose handling. Furthermore, tumors do not consume glucose as their sole nutrient, and their use of other substrates is also exploited with PET (*2,3*). For example, analogs of methionine or tyrosine labeled with ^{18}F or ^{11}C have been used successfully, and their accumulation within tumors probably reflects increased surface expression of amino acid transporters in cancer cells (*4*). Among the other nutrients consumed by tumors, glutamine is the most versatile and probably the most rapidly consumed (*5*). Glutamine is the most abundant amino acid in plasma and occupies a unique niche in intermediary metabolism by providing a major interorgan shuttle for both nitrogen and carbon (*6*). Here, we discuss the reasons why glutamine is a crucial nutrient for the maintenance and growth of tumors and why glutamine metabolism is an appealing target for new molecular imaging strategies in cancer.

GLUTAMINE METABOLISM IN CANCER CELLS

Glutamine's function as a source of both nitrogen and carbon makes it a crucial nutrient during cell proliferation (Fig. 1). Glutamine contains amino and amido nitrogens, which are either transferred to metabolic intermediates in the synthesis of nucleic acids, proteins, and hexosamines or released as ammonia. Although a large fraction of both these groups is ultimately secreted from rapidly dividing cancer cells, proliferation cannot occur unless some of this nitrogen is retained for the formation of complex molecules (*7*). In simple models of cell growth, the role as a nitrogen donor appears to explain some of the growth-retardant effects of glutamine deprivation (*8,9*). Hexosamines, particularly uridine diphosphate–linked *N*-acetylglucosamine, are used in posttranslational protein modifications and are required for glutamine-dependent cell growth and proliferation (*10*). Hexosamine biosynthesis integrates glucose and glutamine metabolism because the rate-limiting step is the addition of the γ-amido group of glutamine to a hexose sugar by the enzyme glutamine fructose-6-phosphate amidotransferase. In hematopoietic cells, *N*-acetylglucosamine and N-linked glycosylation of the IL-3 receptor

FIGURE 1. Glutamine metabolism in cancer cells and its regulation by oncogenes and tumor suppressors. After glutamine is imported into cell through surface transporters such as ASCT1 or SN2, most of it either donates nitrogen to macromolecules or is deamidated by glutaminases, which remove γ-nitrogen to form glutamate (Glu). Glu can be used for biosynthesis of glutathione (GSH) or processed further in mitochondria, where removal of α-nitrogen by aminotransferases or glutamate dehydrogenase (GDH) produces α-ketoglutarate (α-KG). Expression of glutaminases (GLS, GLS2) is upregulated by c-Myc and p53, respectively. Expression of glutamine synthetase (GS) is driven by β-catenin (β-cat). Ac-CoA = acetyl-coenzyme A; ALT = alanine aminotransferase; AST = aspartate aminotransferase; Cit = citrate; OAA = oxaloacetate; Pyr = pyruvate; TCA = tricarboxylic acid.

α-subunit were required for IL-3 to stimulate glutamine uptake and cell growth (11). Because glutamine is also required for de novo N-acetylglucosamine biosynthesis, the findings suggest a feed-forward mechanism whereby ongoing glutamine uptake propagates growth signals during cell proliferation.

Loss of glutamine's amino and amido groups produces a carbon skeleton (α-ketoglutarate) that is also extensively metabolized. Some cancer cells produce more than 50% of their adenosine triphosphate by oxidizing glutamine-derived α-ketoglutarate in the mitochondria (12). Furthermore, the delivery of glutamine carbon to the tricarboxylic acid cycle facilitates growth by maintaining function of the cycle even as intermediates are removed to supply biosynthetic pathways such as lipid synthesis (Fig. 1). This process, termed anaplerosis, can be viewed as the sum of all metabolic pathways that produce oxaloacetate without first passing through acetyl-coenzyme A. In some cancer cell lines, a high fraction of anaplerosis is supplied by glutamine, despite the fact that many other nutrients, including glucose, can be used for anaplerosis (7). Glutamine's dominant role as an anaplerotic precursor may relate both to its abundance and to the importance of

nitrogen-donating reactions that culminate in formation of α-ketoglutarate.

Glutamine also helps mitigate the effects of reactive oxygen species, which are formed as a result of the high-flux metabolic state of rapid cell growth. After deamidation of glutamine, the resulting glutamate can condense with cysteine to form the dipeptide precursor of glutathione, a major antioxidant. Mammalian cells can activate expression of genes involved in glutamine catabolism during reactive oxygen species–induced stress. For example, cells exposed to hydrogen peroxide or reactive oxygen species–inducing chemotherapeutics activate expression of *GLS2*, which encodes one of the glutaminases that convert glutamine to glutamate (13). This correlates with enhanced glutathione abundance. Stress-induced *GLS2* expression is regulated by the tumor suppressor p53, and overexpressing *GLS2* reduces colony formation in tumor cells (13). Thus, *GLS2* may function in a tumor suppression pathway.

Other changes in glutamine metabolism accompany malignant transformation, and these effects depend on the molecular drivers of transformation. Enhanced activity of the oncogenic transcription factor c-Myc drives glutamine metab-

olism by increasing the expression of the surface transporters ASCT2 and SN2 and of the kidney-type glutaminase encoded by the gene *GLS* (*14,15*). Importantly, cells with enhanced c-Myc were exquisitely sensitive to glutamine withdrawal (*14,16*). By contrast, other tumor cells seem to increase their capacity to produce glutamine from glutamate. This reaction requires the condensation of glutamate and ammonia by the enzyme glutamine synthetase. Expression of glutamine synthetase correlates with activating mutations in β-catenin in mice and humans (*17*). Enhanced β-catenin activity is observed in numerous human cancers, including basal cell carcinomas, hepatomas, and colorectal cancers. Although the contribution of glutamine synthetase to tumor initiation or progression is unknown, it is possible that this enzyme alleviates glutamine dependence and allows cells to generate a pool of glutamine for biosynthetic reactions or other purposes.

Over the years there have been several efforts to inhibit glutamine catabolism in tumors, including in humans. Non-selective inhibitors such as 6-diazo-5-oxo-L-norleucine, an amino acid analog that inhibits glutamine fructose-6-phosphate amidotransferase, glutaminase, and other glutamine-dependent reactions, were in clinical trials as early as the 1950s but found to be ineffective or toxic. More recently, a few reports have described agents intended to target glutaminase selectively. One of these, a benzo[a]phenanthridinone compound, was identified in a screen for small-molecule inhibitors of Rho guanosine triphosphatase–mediated transformation. The most active of these compounds was subsequently found to be a glutaminase inhibitor, and it inhibited the growth of glutaminase-expressing lymphoma cells in mouse xenograft experiments (*18*). An allosteric glutaminase inhibitor, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), was studied in the context of the R132H mutation in isocitrate dehydrogenase-1 (*IDH1*) (*19*). This mutation, found frequently in low-grade gliomas, causes the enzyme to convert α-ketoglutarate into 2-hydroxyglutaric acid, an "onco-metabolite" suspected of contributing to tumorigenesis (*20*). BPTES suppressed α-ketoglutarate levels in astrocytes and preferentially inhibited the growth of cells expressing mutant *IDH1* (*19*). The success of these preliminary studies is stimulating industry-sponsored programs to identify new glutaminase inhibitors with even higher specificity and potency.

OPPORTUNITIES IN GLUTAMINE-BASED IMAGING

Because many of the metabolic functions supplied by glutamine are independent of those supplied by glucose, imaging glutamine metabolism would provide a window into aspects of tumor biology different from those shown by ^{18}F-FDG PET. One can imagine several scenarios in which glutamine-based PET would complement ^{18}F-FDG and other nutrient analogs. First, some malignancies lack the high rates of glucose uptake necessary for identification by ^{18}F-FDG PET; prostate and bronchoalveolar carcinomas, carcinoid tumors, and low-grade lymphomas fall into this category. It is possible that a subset of these tumors uses glutamine as an alternative nutrient and might be more easily identified with a glutamine-based tracer. Second, these agents would be useful in patients subjected to drugs that suppress glucose uptake, such as inhibitors of the

signaling pathway phosphatidylinositol-3′-kinase/protein kinase B (Akt)/mammalian target of rapamycin. In culture, cells exposed to these agents require ongoing glutamine use to maintain survival when glucose metabolism is compromised (*21*). Combining ^{18}F-FDG PET with glutamine-based PET during therapy might identify tumors in which persistent glutamine metabolism will support cell survival and negatively affect the outcome. Third, the reliability of ^{18}F-FDG PET is limited when the tumor is adjacent to normal tissues in which ^{18}F-FDG is concentrated (e.g., the heart and brain). Because glutamine consumption is low in these tissues, glutamine-based PET would provide improved contrast between the tumor and normal tissue. Fourth, it might be possible to predict genetic alterations in the tumors based on glutamine uptake in vivo and eventually to tailor therapy on the basis of this information. ^{18}F-FDG PET is successful as a general imaging strategy in cancer precisely because enhanced glucose uptake is a common consequence of many different mutations. But this limits its ability to predict the presence of a specific mutation. If enhanced glutamine metabolism is restricted to a smaller subset of tumors (e.g., those with c-*myc* amplification), then glutamine imaging could be quite informative.

In principle, glutamine could be imaged using ^{11}C or ^{13}N as the radioisotope. The very short half-life of [13]N (10 min) might make it feasible to plan combined, same-day imaging studies to detect tumor glutamine uptake—using ^{13}N-labeled glutamine first and then ^{18}F-FDG PET after an acceptable number of ^{13}N half-lives had passed. However, the intermediary metabolism of glutamine poses some challenges to using ^{13}N or ^{11}C because a large fraction of glutamine's carbon and nitrogen is rapidly exported from glutaminolytic cells (*7*). The amido (γ) nitrogen, in particular, is liberated as ammonia by glutaminase, then secreted. The complete glutaminolytic pathway results in the transfer of glutamine-derived carbon to lactate, which is also secreted. Tumors with highly active glutamine synthetase might be amenable to ^{13}N-ammonia PET, since the condensation of this tracer into newly formed glutamine would trap it inside the cell (*22*). An alternative approach is to label analogs of glutamine with [18]F. Panels of γ-fluorinated derivatives of glutamine and glutamate have been prepared and are readily imported into glutaminolytic tumor cells at rates comparable to ^{18}F-FDG (*23,24*).

Magnetic resonance spectroscopy can also be used to evaluate glutamine and its metabolites within tumors. At high magnetic fields (e.g., 7 T), it is possible to differentiate glutamine from glutamate, glutathione, and γ-amino-butyric acid by ^{1}H magnetic resonance spectroscopy in the brain (*25*). Perturbations of these pools in tumors may signify novel biologic properties and add to the value of clinical magnetic resonance spectroscopy. However, the ideal form of metabolic imaging would support some estimation of bona fide metabolic flux—that is, observation and quantification of the transfer of carbon or nitrogen from substrate to product within the tissue of interest. Tracer studies to observe the metabolism of [13]C- or ^{15}N-labeled glutamine have been used for decades, but in vivo detection of these nuclei is limited by their low abundance and sensitivity. One potential approach is to enhance the sensitivity using inverse detection of spin-coupled protons; this has been

used successfully to monitor ^{15}N metabolism in cancer cell lines (26). Another approach, dynamic nuclear polarization ("hyperpolarization"), massively increases the signal by temporarily transferring the spin state of an unpaired electron to a nuclear spin, usually that of ^{13}C. This causes a signal enhancement of 10,000-fold or more (27), making it feasible to detect carbon–carbon transfers in real time. There has been significant interest in using hyperpolarized ^{13}C to image metabolic fluxes in tumors, particularly the transfer of carbon from pyruvate to lactate by lactate dehydrogenase (28). Hyperpolarization has been used to detect the conversion of [5-^{13}C]glutamine to [5-^{13}C]glutamate in cancer cells (29). This single metabolic conversion potentially integrates several individual activities required for tumor cell growth, including glutaminase and nitrogen donation steps in the synthesis of nucleotides and hexosamines. Hyperpolarization of ^{15}N has been performed successfully for some nitrogenous compounds (30), and if this could be extended to ammonia or glutamine, there could be several useful applications in cancer imaging.

CONCLUSION

Glutamine is an extremely versatile nutrient that contributes to many aspects of intermediary metabolism in cancer cells. It is particularly important in the formation of the macromolecules required for cell proliferation and resistance to oxidative stress. Because glutamine metabolism is altered during malignant transformation, imaging strategies that target glutamine should provide a useful window into tumor biology that would complement ^{18}F-FDG PET and other current techniques. As we identify more roles for this critical nutrient in tumor biology, it will be advantageous to harness glutamine-based imaging as a research and clinical tool in cancer.

ACKNOWLEDGMENTS

REFERENCES

1. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. *Curr Opin Genet Dev.* 2008;18:54–61.
2. Basu S, Alavi A. Molecular imaging (PET) of brain tumors. *Neuroimaging Clin N Am.* 2009;19:625–646.
3. Yu EY, Muzi M, Hackenbracht JA, et al. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. *Clin Nucl Med.* 2011;36:192–198.
4. Zhu A, Lee D, Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. *Semin Oncol.* 2011;38:55–69.
5. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. *Science.* 2010;330:1340–1344.
6. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. *Oncogene.* 2010;29:313–324.
7. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc Natl Acad Sci USA.* 2007;104:19345–19350.
8. Meng M, Chen S, Lao T, Liang D, Sang N. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. *Cell Cycle.* 2010;9:3921–3932.
9. Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. *PLoS ONE.* 2009;4:e4715.
10. Lagranha CJ, Doi SQ, Pithon-Curi TC, Curi R, Sellitti DF. Glutamine enhances glucose-induced mesangial cell proliferation. *Amino Acids.* 2008;34:683–685.
11. Wellen KE, Lu C, Mancuso A, et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. *Genes Dev.* 2010;24:2784–2799.
12. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. *J Biol Chem.* 1979;254:2669–2676.
13. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. *Proc Natl Acad Sci USA.* 2010;107:7455–7460.
14. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proc Natl Acad Sci USA.* 2008;105:18782–18787.
15. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature.* 2009;458:762–765.
16. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. *J Cell Biol.* 2007;178:93–105.
17. Cadoret A, Ovejero C, Terris B, et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. *Oncogene.* 2002;21:8293–8301.
18. Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. *Cancer Cell.* 2010;18:207–219.
19. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. *Cancer Res.* 2010;70:8981–8987.
20. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature.* 2009;462:739–744.
21. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. *Cancer Res.* 2009;69:7986–7993.
22. Xiangsong Z, Dianchao Y, Anwu T. Dynamic ^{13}N-ammonia PET: a new imaging method to diagnose hypopituitarism. *J Nucl Med.* 2005;46:44–47.
23. Qu W, Zha Z, Ploessl K, et al. Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors. *J Am Chem Soc.* 2011;133:1122–1133.
24. Krasikova RN, Kuznetsova OF, Fedorova OS, et al. 4-[^{18}F]fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization. *J Med Chem.* December 3, 2010 [Epub ahead of print].
25. Choi C, Dimitrov IE, Douglas D, et al. Improvement of resolution for brain coupled metabolites by optimized ^{1}H MRS at 7T. *NMR Biomed.* 2010;23:1044–1052.
26. Street JC, Delort AM, Braddock PS, Brindle KM. A $^{1}H/^{15}N$ n.m.r. study of nitrogen metabolism in cultured mammalian cells. *Biochem J.* 1993;291:485–492.
27. Golman K, Ardenkjaer-Larsen JH, Petersson JS, Mansson S, Leunbach I. Molecular imaging with endogenous substances. *Proc Natl Acad Sci USA.* 2003;100:10435–10439.
28. Kurhanewicz J, Vigneron DB, Brindle K, et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. *Neoplasia.* 2011;13:81–97.
29. Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. ^{13}C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized ^{13}C-labeled glutamine. *Magn Reson Med.* 2008;60:253–257.
30. Gabellieri C, Reynolds S, Lavie A, Payne GS, Leach MO, Eykyn TR. Therapeutic target metabolism observed using hyperpolarized ^{15}N choline. *J Am Chem Soc.* 2008;130:4598–4599.